چكيده لاتين :
Background: About 40%-60% of schizophrenic patients are
resistant to ordinary treatment, which result from interference
with different neurotransmitter systems in the process of disease.
The aim of present study was to determine the effect of
famotidine on several symptoms of schizophrenia which was
nonresponsive to neuroleptic treatment.
Methods: 30 schizophrenic patients previously nonresponsive
to ordinary treatment were categorized into two groups. Famotidine
group received perphenazine plus famotidine and placebo
group received perfenazine plus a placebo. Patients in
both groups were followed for 6 weeks and assessed by the
positive and negative symptom scales (PANSS) at weeks 0, 2
and 6 of the treatment.
Results: Both groups were similar in terms of positive and
negative symptoms. In the placebo group, the total scores of
PANSS (severity of the disease) did not change significantly.
However, based on the total scores of PANSS, there was a
significant difference between both famotidine and placebo
groups at the end of sixth week (P(LESS THAN)0.05). In terms of general
psychopathology scale and aggressive risk, there was also a
significant difference between both famotidine and control
groups at the end of sixth week.
Conclusion: Famotidine can improve the symptoms of schizophrenic
patients who were not responsive to neuroleptics.
